NAME
Xiaochao Ma / TITLE
Assistant Professor
ADDRESS
Department of Pharmacology, Toxicology and Therapeutics
University of KansasMedicalCenter
4089 KLSIC, MS 1018, 3901 Rainbow Boulevard
Kansas City, Kansas66160
Phone: (913) 588-1749, Fax: (913) 588-7501
Email:
EDUCATION & TRAINING
Year / University / Institute / Study Field / Degree
2003-2008 / National Institutes of Health, Bethesda, Maryland, USA / Drug metabolism & Metabolomics / Postdoc
1998-2003 / Chinese Academy of Sciences, Shanghai, China / Pharmacology & Toxicology / Ph.D.
1993-1998 / HenanMedicalUniversity, Zhengzhou, China / Clinical Medicine / B.M.
PROFESSIONAL EXPERIENCES
(1) 2008 to present: Assistant Professor, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center. Research Interests:Drug-drug interactions, Drug-induced liver injury, Toxicometabolomics.
My current research focuses on the role of xenobiotic nuclear receptors in drug metabolism and metabolism-mediated liver injury. Pregnane X receptor (PXR) is one of the most important xenobiotic nuclear receptors regulating a large network of genes including those encoding metabolic enzymes and transporters. Recent advances in mouse models, including Pxr-null, PXR-humanized, and CYP3A4-transgenic mice, provide ideal tools for investigating the roles of human PXR and CYP3A4 in vivo. My laboratory utilizes these genetically engineered mouse models to investigate the mechanisms of drug-induced liver injury. In addition, we are interested in identifying small molecule biomarkers of drug-induced liver injury using an LC-MS-based metabolomic approach. Specific responding biomarkers will be used for elucidating the mechanisms of drug-induced liver injury.
(2) 2003 to 2008: Postdoctoral training in Laboratory of Metabolism, National Institutes of Health. Research field: Transgenic mouse and its application in the studies of drug metabolism and toxicity; Metabolomics. Mentor: Dr. Frank Gonzalez.
(3) 1998 to 2003: Ph.D. study in the Center for Drug Safety Evaluation and Research, the State Key Laboratory of Drug Research, Shanghai Institute of Meteria Medica, ChineseAcademy of Sciences. Research field: Role of cytochrome P450s in drug metabolism and toxicity. Mentor: Dr. Zenghong Tu.
RESEARCH SUPPORTS
Ongoing
  • R01, NIDDK, 02/20/2012—01/31/2017. Direct funds: $1,087,500.00. Mechanisms of adverse effects of anti-tuberculosis drugs. Role: PI.
Pending
  • R01, NIAID, 10/01/2012-09/30/2017. Drug-induced liver injury associated with anti-retroviral therapy. Role: PI.
Completed
  • COBRE P20 RR021940 07/14/2008—02/20/2012. Centers of Biomedical Research Excellence (COBRE), Nuclear receptors in liver health and disease. Role: Project leader. Direct funds: $135,000.00 per year.
  • Lied Endowed Basic Science Program, KUMC, 05/10/2011—05/09/2012. Drug-Induced Liver Injury Associated with Anti-Retroviral Therapy. Direct funds: $30,000.00.
  • Bridging Grant Program, KUMC, 04/01/2011—03/31/2012. Role of Pregnane X Receptor in Hepatotoxicity Associated with Rifampicin-isoniazid Co-therapy. Direct funds: $35,000.00. (This is a different project from the current application).
  • Kansas IDeA Network of Biomedical Research Excellence (K-INBRE), 10/05/2009—04/30/2010. Direct funds: $40,000.00.

HONORS AND AWARDS
  • Fellows Award for Research Excellence, 2007-2008, sponsored by NIH.
  • Fellows Award for Research Excellence 2006-2007, sponsored by NIH.
  • Postdoctoral Scientist Award in Toxicology (1st place), 2007, sponsored by the American Society for Pharmacology and Experimental Therapeutics (ASPET).

PROFESSIONAL MEMBERSHIPS
  • The American Society for Pharmacology and Experimental Therapeutics (ASPET)
  • International Society for the Study of Xenobiotics (ISSX)
  • Sigma Xi, The Scientific Research Society

PUBLICATIONS (Recent 5 years)
1: Li F, Lu J, Ma X. CPY3A4-mediated lopinavir bioactivation and its inhibition
by ritonavir. Drug Metab Dispos. 2012 Jan;40(1):18-24.
2: Li F, Lu J, Ma X. Metabolomic screening and identification of the
bioactivation pathways of ritonavir. Chem Res Toxicol. 2011 Dec
19;24(12):2109-14.
3: Li F, Miao Y, Zhang L, Neuenswander SA, Douglas JT, Ma X. Metabolomic analysis
reveals novel isoniazid metabolites and hydrazones in human urine. Drug Metab
Pharmacokinet. 2011;26(6):569-76.
4: Guo Y, Li F, Ma X, Cheng X, Zhou H, Klaassen CD. CYP2D plays a major role in
berberine metabolism in liver of mice and humans. Xenobiotica. 2011
Nov;41(11):996-1005.
5: Li F, Lu J, Ma X. Profiling the reactive metabolites of xenobiotics using
metabolomic technologies. Chem Res Toxicol. 2011 May 16;24(5):744-51.
6: Li F, Lu J, Wang L, Ma X. CYP3A-mediated generation of aldehyde and hydrazine
in atazanavir metabolism. Drug Metab Dispos. 2011 Mar;39(3):394-401.
7: Cheng J, Ma X, Gonzalez FJ. Pregnane X receptor- and CYP3A4-humanized mouse
models and their applications. Br J Pharmacol. 2011 Jun;163(3):461-8.
8: Wang L, Li F, Lu J, Li G, Li D, Zhong XB, Guo GL, Ma X. The Chinese herbal
medicine Sophora flavescens activates pregnane X receptor. Drug Metab Dispos.
2010 Dec;38(12):2226-31.
9: Cheng J, Shah YM, Ma X, Pang X, Tanaka T, Kodama T, Krausz KW, Gonzalez FJ.
Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication
of human pregnane X receptor activation. J Pharmacol Exp Ther. 2010
Oct;335(1):32-41.
10: Niu S, Li F, Tan DX, Zhang L, Idle JR, Gonzalez FJ, Ma X. Analysis of
N1-acetyl-N2-formyl-5-methoxykynuramine/N1-acetyl-5-methoxy-kynuramine formation
from melatonin in mice. J Pineal Res. 2010 Sep;49(2):106-14.
11: Li F, Wang L, Guo GL, Ma X. Metabolism-mediated drug interactions associated
with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010
May;38(5):871-8.
12: Guettier JM, Gautam D, Scarselli M, Ruiz de Azua I, Li JH, Rosemond E, Ma X,
Gonzalez FJ, Armbruster BN, Lu H, Roth BL, Wess J. A chemical-genetic approach to
study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S
A. 2009 Nov 10;106(45):19197-202.
13: Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human
pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity.
Drug Metab Dispos. 2009 Aug;37(8):1611-21.
14: Cho JY, Kang DW, Ma X, Ahn SH, Krausz KW, Luecke H, Idle JR, Gonzalez FJ.
Metabolomics reveals a novel vitamin E metabolite and attenuated vitamin E
metabolism upon PXR activation. J Lipid Res. 2009 May;50(5):924-37.
15: Ma X, Cheung C, Krausz KW, Shah YM, Wang T, Idle JR, Gonzalez FJ. A double
transgenic mouse model expressing human pregnane X receptor and cytochrome P450
3A4. Drug Metab Dispos. 2008 Dec;36(12):2506-12.
16: Ma X, Idle JR, Gonzalez FJ. The pregnane X receptor: from bench to bedside.
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):895-908.
17: Ma X, Chen C, Krausz KW, Idle JR, Gonzalez FJ. A metabolomic perspective of
melatonin metabolism in the mouse. Endocrinology. 2008 Apr;149(4):1869-79.
18: Wang T, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Role of pregnane X receptor in
control of all-trans retinoic acid (ATRA) metabolism and its potential
contribution to ATRA resistance. J Pharmacol Exp Ther. 2008 Feb;324(2):674-84.
19: Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ. Rifaximin is
a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007
Jul;322(1):391-8.
20: Chen C, Ma X, Malfatti MA, Krausz KW, Kimura S, Felton JS, Idle JR, Gonzalez
FJ. A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem Res Toxicol. 2007 Mar;20(3):531-42.
21: Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation
ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB
target gene expression. Am J Physiol Gastrointest Liver Physiol. 2007
Apr;292(4):G1114-22.
22: Ma X, Shah Y, Cheung C, Guo GL, Feigenbaum L, Krausz KW, Idle JR, Gonzalez
FJ. The Pregnane X receptor gene-humanized mouse: a model for investigating
drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos. 2007
Feb;35(2):194-200.
23: Ma X, Idle JR, Malfatti MA, Krausz KW, Nebert DW, Chen CS, Felton JS, Waxman
DJ, Gonzalez FJ. Mouse lung CYP1A1 catalyzes the metabolic activation of
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis. 2007
Mar;28(3):732-7.

1